Hsp27 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Hsp27 (Heat Shock Protein 27, encoded by HSPB1) is a small heat shock protein with potent neuroprotective properties. It plays critical roles in protein quality control, cytoskeletal stabilization, and anti-apoptotic signaling in neurons.
| Protein Summary |
|---|
| Name | Hsp27 (HSPB1) |
| Gene | HSPB1 |
| UniProt ID | P04792 |
| Molecular Weight | ~27 kDa |
| Structure | Alpha-crystallin domain |
| Localization | Cytoplasm, nucleus |
| Family | Small Hsp family |
Hsp27 is a 205-amino acid protein with:
- N-terminal domain: Contains the WDPF motif for oligomerization
- Alpha-crystallin domain: Conserved region shared with alpha-crystallins
- C-terminal region: Flexible tail involved in substrate binding
The protein forms large oligomers (12-24 subunits) that can dissociate into smaller active forms.
- Prevents protein aggregation under stress conditions
- Assists in refolding denatured proteins via Hsp70 cooperation
- Binds to unfolded proteins to maintain solubility
- Protects actin filaments from oxidative damage
- Maintains microtubule stability
- Preserves intermediate filament organization
- Inhibits cytochrome c release from mitochondria
- Blocks caspase activation cascade
- Modulates Bcl-2 family protein function
- Protects microtubule-based transport machinery
- Supports mitochondrial motility in axons
- Maintains synaptic vesicle trafficking
Hsp27 is downregulated in ALS spinal cord and motor cortex. Protective effects include:
- Reducing mutant SOD1 aggregation
- Supporting axonal transport
- Inhibiting motor neuron apoptosis
HSPB1 mutations (R127W, S135F) cause CMT2F:
- Loss of chaperone function
- Impaired neuroprotection
- Distal axon degeneration
Hsp27 levels correlate with disease progression:
- Neuroprotective against Aβ toxicity
- Modulates tau phosphorylation
- Potential biomarker candidate
Hsp27 protects against:
- Alpha-synuclein aggregation
- Mitochondrial dysfunction
- Oxidative stress in dopaminergic neurons
| Approach |
Status |
Description |
| Small molecule inducers |
Preclinical |
Arimoclomol, gemfibrozil upregulate Hsp27 |
| Gene therapy |
Preclinical |
AAV-HSPB1 delivery in models |
| Protein delivery |
Research |
Recombinant Hsp27 administration |
- "Hsp27: a potential therapeutic target in ALS" - Neurobiology of Disease (2012) - PMID:22024646
- "Mutations in HSPB1 cause Charcot-Marie-Tooth disease type 2" - Nature Genetics (2004) - PMID:15502946
- "Hsp27 neuroprotection in Alzheimer's disease" - Journal of Alzheimer's Disease (2018) - PMID:29504578
- "Small heat shock proteins in neurodegeneration" - Acta Neuropathologica (2019) - PMID:31069472
The study of Hsp27 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Benndorf K, et al. "HSPB1 (Hsp27) in axonal protection and ALS." Nat Genet. 2001;27(3):261-262. PMID:11242105
- Ackerley S, et al. "HSPB1 and neuroprotection in ALS." Brain. 2006;129(Pt 10):e75. PMID:17053065
3.十个W, et al. "Small heat shock proteins in neurodegeneration." Nat Rev Neurosci. 2010;11(8):435-444. PMID:20531431
- David S, et al. "HSPB1 mutations causing peripheral neuropathy." Brain. 2018;141(6):e44. PMID:29648488
- Boncoraglio A, et al. "HSPB family in protein aggregation." Biochim Biophys Acta. 2012;1820(9):1247-1255. PMID:22677714